

For Public Release
NZX Limited
Wellington

04 September 2023

Publication of Research Report

The Board of Cannasouth Limited (NZX:CBD) commissioned an issuer sponsored research report on the Company from leading biotech stock research firm, Pitt Street Research Pty Ltd, based in Sydney.

The report is available on both Cannasouth and Pitt Street Research's websites at:

<https://www.cannasouth.co.nz/investors/reports-and-presentations/>

<https://www.pittstreetresearch.com/cannasouth>

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO / Company Secretary
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqlis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>